{"id":751581,"date":"2023-04-26T16:29:08","date_gmt":"2023-04-26T20:29:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/"},"modified":"2023-04-26T16:29:08","modified_gmt":"2023-04-26T20:29:08","slug":"sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/","title":{"rendered":"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, April  26, 2023  (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually.<\/p>\n<p>\n        <strong>Presentation Details:<\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> \u201cA randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator&#8217;s choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.\u201d<\/p>\n<p>\n        <strong>Presenter: <\/strong>Omer Jamy, M.D. Principal Investigator of REGAL Study at the University of Alabama at Birmingham<\/p>\n<p>\n        <strong>Presentation Type:<\/strong> Poster<\/p>\n<p>\n        <strong>Session Title: <\/strong>Hematologic Malignancies\u2014Leukemia, Myelodysplastic Syndromes, and Allotransplant<\/p>\n<p>\n        <strong>Clinical Trial Registration Number: <\/strong>NCT04229979<\/p>\n<p>\n        <strong>Abstract Number:<\/strong> TPS7074<\/p>\n<p>\n        <strong>Session Date and Time: <\/strong>Monday, June 5, 2023, 9:00 AM \u2013 12:00 PM EDT<\/p>\n<p>\n        <strong>Location:<\/strong> Hall A, On Demand<\/p>\n<p>The full abstract will be published by ASCO on May 25, 2023 at 5:00 pm EDT.<\/p>\n<p>\n        <strong>About SELLAS Life Sciences Group, Inc.<\/strong><br \/>\n        <br \/>SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS\u2019 lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China. For more information on SELLAS, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uRfuewyLItEy9tcmLUCj1pN6K2o2GqYBOvoEe8K6fotyWIY6XuD7MdFwEkE9vxxR4-A76fY0UgPaQE7IwzHeRMGVn95pZitZMemr2Ojo07PSRs2ncWGPVk4qCgg29BPm\" rel=\"nofollow noopener\" target=\"_blank\">www.sellaslifesciences.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements. All statements other than statements of historical facts are \u201cforward-looking statements,\u201d including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as \u201cplan,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cintend,\u201d or \u201ccontinue\u201d and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption \u201cRisk Factors\u201d in SELLAS\u2019 Annual Report on Form 10-K filed on March 16, 2023 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS\u2019 forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. <\/em>\n      <\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Bruce Mackle<br \/>Managing Director<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KwxnAujWcPkroi_OM--R3ZS3Of7IQVnVwGYyC-73qRd8uA0VRKAjBwqduGJWmG0mWqSjyiTJGkeMDm2YrS58HWHithH8eOE_07He2PtBt1DPqBlOCsQy9RclYzHmXkrZ\" rel=\"nofollow noopener\" target=\"_blank\">SELLAS@lifesciadvisors.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDA3Njc4NTItOWU4NS00NTgwLWEyM2UtZGZiYzA1NDk1NmZhLTExMzU4OTM=\/tiny\/SELLAS-Life-Sciences-Group-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually. Presentation Details: Title: \u201cA randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator&#8217;s choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.\u201d Presenter: Omer Jamy, M.D. Principal Investigator of REGAL Study at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751581","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually. Presentation Details: Title: \u201cA randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator&#8217;s choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.\u201d Presenter: Omer Jamy, M.D. Principal Investigator of REGAL Study at &hellip; Continue reading &quot;SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T20:29:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting\",\"datePublished\":\"2023-04-26T20:29:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/\"},\"wordCount\":571,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/\",\"name\":\"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=\",\"datePublished\":\"2023-04-26T20:29:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting - Market Newsdesk","og_description":"NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) &#8212; SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (\u201cSELLAS\u2019\u2019 or the \u201cCompany\u201d), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced acceptance of an abstract for a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago and virtually. Presentation Details: Title: \u201cA randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator&#8217;s choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.\u201d Presenter: Omer Jamy, M.D. Principal Investigator of REGAL Study at &hellip; Continue reading \"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T20:29:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting","datePublished":"2023-04-26T20:29:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/"},"wordCount":571,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/","name":"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=","datePublished":"2023-04-26T20:29:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjUxMiM1NTYwMDY5IzIxMjQzMjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sellas-life-sciences-announces-abstract-accepted-for-presentation-at-asco-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751581"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751581\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}